Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/22618
Title: Is anti-TNF switching in refractory Still's disease safe and effective?
Authors: AIKAWA, Nadia EmiRIBEIRO, Ana Cristina de MedeirosSAAD, Carla Goncalves SchainPEREIRA, Rosa Maria RodriguesLEVY, MauricioSILVA, Clovis A.BONFA, EloisaCARVALHO, Jozelio Freire de
Citation: CLINICAL RHEUMATOLOGY, v.30, n.8, p.1129-1134, 2011
Abstract: Still's disease (SD) is a rare chronic inflammatory disease characterized by polyarthritis, systemic symptoms, and elevated inflammatory markers. Of note, 74 SD cases were reported with anti-tumoral necrosis factor (TNF) therapy and the experience of switching is limited to five patients. During a 3-year period, SD cases were 1.9% of 319 rheumatic patients that received anti-TNF agents in the infusion center of our University Hospital. In this manuscript, the authors add six new cases of refractory SD who had clinical and laboratory response to TNF blockers and report the outcome of switching in five of them. Partial or complete response was achieved by four of six (66.7%) patients and three of four (75%) required switching. Regarding safety, five of six (83.3%) had adverse events. Anti-TNF treatment with switching seems to be a valid approach for refractory SD patients.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica


Files in This Item:
File Description SizeFormat 
art_AIKAWA_Is_antiTNF_switching_in_refractory_Stills_disease_safe_2011.PDF
  Restricted Access
publishedVersion (English)110.03 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.